For: | Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v7/i28/2792.htm |
Number | Citing Articles |
1 |
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020; 56(5): 564 doi: 10.1007/s11262-020-01776-y
|
2 |
Anissa Chouikha, Marwa Khedhiri, Hatem Triki, Walid Hammemi, Amel Sadraoui, Henda Touzi, Ahlem Ben Yahia, Amel Chtourou, Saba Gargouri, Lamia Feki Ben Rajah, Hela Hakim Karray, Henda Triki. Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study. Archives of Virology 2021; 166(2): 501 doi: 10.1007/s00705-020-04918-7
|
3 |
Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Małgorzata Pawłowska, Ewa Janczewska, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczyński, Krzysztof Tomasiewicz, Anna Piekarska, Rafał Krygier, Jolanta Citko, Olga Tronina, Krystyna Dobrowolska, Robert Flisiak. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. Journal of Clinical Medicine 2022; 11(2): 389 doi: 10.3390/jcm11020389
|
4 |
Naiema K. Ali, Ragaa R. Mohamed, Bothina E. Saleh, Manal M. Alkady, Eman S. Farag. Occult hepatitis C virus infection among haemodialysis patients. Arab Journal of Gastroenterology 2018; 19(3): 101 doi: 10.1016/j.ajg.2018.09.001
|
5 |
Dina Ragab, Dalia Samaha, Nesrine Mohamed, Mona Rafik, Walid Abdel Hady. Chronic hepatitis C virus infection impairs natural killer cells–dendritic cells cross‐talk: Anin vitroculture study. Microbiology and Immunology 2021; 65(2): 76 doi: 10.1111/1348-0421.12858
|
6 |
Caroline E Boeke, Lindsey Hiebert, Imam Waked, Tengiz Tsertsvadze, Lali Sharvadze, Maia Butsashvili, Mamuka Zakalashvili, Win Naing, Neil Gupta, Fredrick Kateera, Craig McClure, John W Ward, Christian B Ramers. Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries. Clinical Infectious Diseases 2022; 74(3): 513 doi: 10.1093/cid/ciab461
|
7 |
Ali Jibran Mecci, Michelle Cheung. Encyclopedia of Life Sciences. 2017; : 1 doi: 10.1002/9780470015902.a0024786
|
8 |
G. Sanchez Antolin, M. Testillano, J.M. Pascasio, I. Narvaez Rodriguez, M. Prieto, A. Otero, J.I. Herrero, M. Londoño, I. Fernandez Vazquez, L. Castells, Xavier Xiol, Maria Luisa Gonzalez Dieguez, Mario Romero Cristobal, Jose Antonio Pons Miñano, Sonia Pascual Bartolome, Jose Luis Montero, Ana Arencibia, Sara Lorente, Esther Molina, Maria Dolores Espinosa, Valentin Cuervas-Mons, Emilio Fabrega Garcia. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplantation Proceedings 2016; 48(9): 3013 doi: 10.1016/j.transproceed.2016.08.034
|
9 |
Youssef M. Mosaad, Shereen S. Metwally, Raghda E. Farag, Zakeria F. Lotfy, Hosam E. AbdelTwab. Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV. Immunological Investigations 2019; 48(3): 321 doi: 10.1080/08820139.2018.1527851
|
10 |
AbdullahS Alghamdi, Mohammed Alghamdi, FaisalM Sanai, Hamdan Alghamdi, Faisal Aba-Alkhail, Khalid Alswat, Mohammed Babatin, Adel Alqutub, Ibrahim Altraif, Faleh Alfaleh. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi Journal of Gastroenterology 2016; 22(8): 25 doi: 10.4103/1319-3767.188067
|
11 |
Sevin Kirdar, Neriman Aydin, Yasin Tiryaki, Bulent Ertugrul, Adil Coskun, Mehmet Bilgen. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018; 126(2): 109 doi: 10.1111/apm.12790
|
12 |
Awat Hasan, Zhian Ramzi, Mohammed Alshekhani. Seroprevalence and Genotypic Distribution Patterns of Hepatitis C Virus among Infected Patients from Sulaimaniyah Province: Iraq. Journal of Zankoy Sulaimani - Part A 2023; 25(1): 9 doi: 10.17656/jzs.10889
|
13 |
Andres Tabernilla, Ignacio Rego-Pérez, Marta Grandal, Berta Pernas, Sonia Pértega, Manuel Delgado, Ana Mariño, Hortensia Álvarez, Alvaro Mena, Iria Rodríguez-Osorio, Jose Domingo Pedreira, Francisco Javier Blanco, Eva Poveda. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. JAIDS Journal of Acquired Immune Deficiency Syndromes 2016; 73(2): 149 doi: 10.1097/QAI.0000000000001097
|
14 |
Gadissa Bedada Hundie, V. Stalin Raj, Daniel GebreMichael, Suzan D. Pas, Bart L. Haagmans, Jason Blackard. Genetic diversity of hepatitis C virus in Ethiopia. PLOS ONE 2017; 12(6): e0179064 doi: 10.1371/journal.pone.0179064
|
15 |
Ahmed Nagaty, Ekram W. Abd El-Wahab, Tatsuo Kanda. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLOS ONE 2017; 12(10): e0184654 doi: 10.1371/journal.pone.0184654
|
16 |
Mohamed Aboushady, Ahmed Alwassief, Mohamed Abdelrazik, Dina Ziada, Hossam Shahba, Amr Elmestikawy, Ashraf Elbahrawy. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. Journal of Interferon & Cytokine Research 2019; 39(9): 539 doi: 10.1089/jir.2019.0041
|
17 |
G. Camus, B. Han, T. Asselah, D. Hsieh, H. Dvory‐Sobol, J. Lu, E. Svarovskaia, R. Martin, B. Parhy, M. D. Miller, D. M. Brainard, K. Kersey, A. Abergel, H. Mo. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. Journal of Viral Hepatitis 2018; 25(2): 134 doi: 10.1111/jvh.12795
|
18 |
Masoud Keikha, Hossein Kamali, Kiarash Ghazvini, Mohsen Karbalaei. Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections. VirusDisease 2022; 33(4): 445 doi: 10.1007/s13337-022-00790-y
|
19 |
Mainga Onchong’a Robert, Odari Okoth Eddy, Borus Kimutai Peter, Ole Kwallah Allan, Murithi Gikunda James, Osero Ong’ondo Bernard, Ruttoh Kiplangat Vincent, Mwandawiro Smiti Charles, Lihana Wekesa Raphael. Characterization of Hepatitis C virus circulating among injecting drug users (IDU) in Kilifi county, Kenya. Journal of Human Virology & Retrovirology 2020; 8(2): 23 doi: 10.15406/jhvrv.2020.08.00217
|
20 |
Kholoud A. Saad, Mohammed A. Eldawy, Khaled M. Elokely. Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a. Journal of Molecular Modeling 2023; 29(1) doi: 10.1007/s00894-022-05420-4
|
21 |
Allison M. Bell, Jamie L. Wagner, Katie E. Barber, Kayla R. Stover. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. International Journal of Hepatology 2016; 2016: 1 doi: 10.1155/2016/3852126
|
22 |
Mohamed A. Daw, Abdallah El-Bouzedi, Mohamed O. Ahmed, Aghnyia A. Dau, Mohamed M. Agnan. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Medicine and Infectious Disease 2016; 14(5): 517 doi: 10.1016/j.tmaid.2016.05.020
|
23 |
Dalia Omran, Mohamed Alboraie, Rania A Zayed, Mohamed-Naguib Wifi, Mervat Naguib, Mohamed Eltabbakh, Mohamed Abdellah, Ahmed Fouad Sherief, Sahar Maklad, Heba Hamdy Eldemellawy, Omar Khalid Saad, Doaa Mohamed Khamiss, Mohamed El Kassas. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World Journal of Gastroenterology 2018; 24(38): 4330-4340 doi: 10.3748/wjg.v24.i38.4330
|
24 |
Dimitrios Paraskevis, Evangelia Georgia Kostaki, Anna Kramvis, Gkikas Magiorkinis. Hepatitis C: Epidemiology, Prevention and Elimination. 2021; : 55 doi: 10.1007/978-3-030-64649-3_3
|
25 |
Moataz M. Sayed, Ahmed I. El-Shafie, Ahmed Fathy Hilal, Hoda A. Abdelsattar. Can hepatitis C virus core antigen be used as a reliable marker of viral load for hepatitis C virus infection in genotype 4?. Egyptian Liver Journal 2017; 7(1 and 2): 1 doi: 10.1097/01.ELX.0000523559.96944.09
|
26 |
Andréa Monteiro Tarragô, Grenda Leite Pereira, Flamir da Silva Victória, Adriana Malheiro Alle Marie, Marilú Barbieri Victória. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Revista da Sociedade Brasileira de Medicina Tropical 2017; 50(6): 861 doi: 10.1590/0037-8682-0094-2017
|
27 |
Aly Atef Shoun, Rania Abozahra, Kholoud Baraka, Mai Mehrez, Sarah M. Abdelhamid. Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt. Microorganisms 2022; 10(4): 679 doi: 10.3390/microorganisms10040679
|
28 |
Etienne M. Sokal, Pilar Nannini. Chapter 6.1. Pediatric Chronic Hepatitis B and C. Journal of Pediatric Gastroenterology and Nutrition 2018; 66(S1) doi: 10.1002/j.1536-4801.2018.tb00053.x
|
29 |
|
30 |
El‐Sayed Ibrahim, Mohamed Abdel‐Samiee, Mohamed I. Youssef, Helmy El‐Shazly, Abd‐ElAleem A.El‐Gendy, Ayman Ahmed Sakr, Doaa Elwazzan, Mervat Ragab Nassar, Amr Aly Elshormilisy, Ahmad Madkour, Mostafa Kamal, Yasmine M. Amrousy, Sally Waheed Elkhadry, Eman Abdelsameea. Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct‐acting antiviral therapy. Journal of Viral Hepatitis 2021; 28(2): 279 doi: 10.1111/jvh.13426
|
31 |
Neven A. Ebrahim, Hussein Abdelaziz Abdalla, Neimat Abd Elhakam Yassin, Aya Elsayed Maghrabia, Amira Ibrahim Morsy. Effect of Sofosbuvir on rats’ ovaries and the possible protective role of vitamin E: biochemical and immunohistochemical study. Anatomy & Cell Biology 2023; 56(4): 526 doi: 10.5115/acb.23.079
|
32 |
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. Journal of Advanced Research 2018; 10: 39 doi: 10.1016/j.jare.2018.01.004
|
33 |
Ehab H. Mattar, Hussein A. Almehdar, Vladimir N. Uversky, Elrashdy M. Redwan. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4. Molecular BioSystems 2016; 12(9): 2785 doi: 10.1039/C6MB00283H
|
34 |
Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S.M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology 2019; 70(3): 554 doi: 10.1016/j.jhep.2018.10.032
|
35 |
Nicola Coppola, Loredana Alessio, Lorenzo Onorato, Caterina Sagnelli, Margherita Macera, Evangelista Sagnelli, Mariantonietta Pisaturo. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infectious Diseases of Poverty 2019; 8(1) doi: 10.1186/s40249-019-0528-6
|
36 |
Rania H. Khalifa, Rasha Mohamad Hosny Shahin, Reham Emad Eldin Aboukhalil, Mohamed A. Marie, Amr M. El-deeb, Nermine Magdi Riad. Digging more in the genetic risk prediction of hepatitis C virus epidemic in Egypt: Apoptosis genes polymorphisms in the susceptibility of hepatitis C virus and association with viral load. Virus Research 2017; 238: 35 doi: 10.1016/j.virusres.2017.05.025
|
37 |
Khalid S. Hassanien, El‐Sayed M. El‐Sayed, Raed S. Ismail, Zakarya M. Zakarya, Gouda K. Helal. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. Journal of Clinical Pharmacy and Therapeutics 2021; 46(4): 942 doi: 10.1111/jcpt.13417
|